They also found that FGL2 secreted on glioma cells could bind to the receptor CD16 on TAMs and promote the Syk/PI3K/AKT/HIF1α signaling pathway, then induce the release of CXCL7, which in turn could act on glioma cells and facilitate their Stem-like transition (23). This evidence concerns the gene FGL2 and central nervous system cancer.